FDA finds new fake batch of cancer drug Avastin

The third case of fake Avastin in the past year has been found, packaged as the Turkish drug Altuzan.

WASHINGTON — The Food and Drug Administration is warning U.S. doctors about another counterfeit version of the cancer drug Avastin, the third case involving the best-selling Roche drug in the past year.

The FDA said in an online post Tuesday that at least one batch of the drug distributed by a New York company does not contain the active ingredient in real Avastin, which is used to treat cancers of the colon, lung, kidney and brain.

The agency is asking doctors to stop using any products from Medical Device King, Pharmalogical or Taranis Medical, another affiliated business.

But an attorney for the Great Neck, N.Y.-based company pushed back against the FDA's claims, saying the company did not distribute the product in question.

"We are unaware of any proof which associates this batch, or any other such counterfeit products, to Pharmalogical," said attorney Richard Gertler, in a statement. He said the company has been cooperating with FDA's ongoing investigation of drugs distributed by a Canadian company, but added that "Pharmalogical has no association with the Canadian company."

The agency warned doctors in April about a similar case of fake Turkish Avastin distributed by a U.K. distributor. Prior to that, the FDA announced in February an investigation into a different batch of fake Avastin distributed to doctors in several states. Both of those cases appeared to involve different networks of distributors than the latest incident.

The FDA said it's currently unclear whether any U.S. patients have received the drug. Specifically, Altuzan labeled with the lot numbers B6022B01 and B6024B01 may be counterfeit. Importing even authentic Altuzan into the U.S. is illegal, since the FDA has only reviewed Avastin as safe and effective.

The agency is asking doctors to stop using any products from Medical Device King, Pharmalogical or Taranis Medical, another affiliated business.

A telephone number listed on Medical Device King's website was not in service. Company representatives did not immediately respond to emails sent Wednesday.

Roche's Genentech unit sells Avastin in 120 countries and manufactures and packages the drug at eight sites worldwide. The drug had sales of $5.8 billion in 2012 and was Roche's second-best selling drug overall. The injectable drug usually sells for about $2,500 per vial.

The FDA warned doctors to be wary of drug prices that seem "too good to be true."

"Deep discounts may be offered because the product is stolen, counterfeit, substandard, or unapproved," the agency states.

Incidents of counterfeiting reported by drugmakers have increased steadily over the past decade, though only about 5 percent of cases are typically reported in the U.S.

The rise in counterfeiting comes as pharmaceutical supply chains increasingly stretch across continents. More than 80 percent of the active ingredients used in U.S. pharmaceuticals are now manufactured overseas, according to a recent congressional report.

 

RELATED from MSN HealthyLiving:

Avastin shows no benefit for earlier colon cancer: Study

Avastin won't extend breast cancer survival: Study

___

MSN News on Facebook and Twitter

Stay up to date on breaking news and current events.

Friend us on Facebook: www.facebook.com/news.msn

Follow us on Twitter: www.twitter.com/msnnews